Table 1.
Plasma HPV DNA in tumor, Clinical staging, and treatment outcome of 50 HPV associated CC patients
| Total | Plasma HPV DNA | ||||
| Positive | Negative | ||||
| Cervical Cancer patient | 50 | 6 | 44 | ||
| Agea | |||||
| <50 | 25 | 3 | 22 | ||
| >50 | 25 | 3 | 22 | ||
| HPV type | |||||
| Ub | 4 | 0 | 4 | ||
| 16 | 28 | 2 | 26 | ||
| 18 | 16 | 4 | 12 | ||
| 33 | 2 | 0 | 2 | ||
| Stage | |||||
| IB | 2 | 0 | 2 | ||
| IIB | 17 | 3 | 14 | ||
| IIIB | 28 | 0 | 28 | ||
| IVB | 1 | 1 | 0 | ||
| Rc | 2 | 2 | 0 | ||
| IIB response to radiotherapy | |||||
| PRd | 3 | 2 | 1 | ||
| CRe | 15 | 1 | 13 | ||
| IIB clinical outcome within | |||||
| one year after complete | |||||
| treatment | |||||
| Rc | 6 | 2 | 4 | ||
| NEDf | 5 | 0 | 5 | ||
| Metastases | |||||
| Positive | 3 | 3 | P = 0001 | 0 | |
| Negative | 47 | 3 | RR = 15.67 | 44 | |
| Histopathology type | |||||
| Squamous | 42 | 5 | 37 | ||
| Adenomatous | 8 | 1 | 7 | ||
a<50 and >50 age less than 50, and above 50, respectively; b U, unknown; c R, recurrence: dPR, partial response; e CR, complete response; f NED, no evidence of disease